Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides

Phase 2NV-387Positive

AI Analysis

Summary

NanoViricides has initiated a Phase II clinical trial of NV-387 for monkeypox treatment in the Democratic Republic of Congo. The trial represents advancement in therapeutic development for infectious disease.

Clinical Trial Data

Phase

Phase II

Importance:5/10

Sentiment:

0.30

clinical_trialmonkeypoxphase_2DRC

Related Companies

$NNVC

Read the original article

Published by yahoo_finance on September 23, 2026 12:30 PM

Read Original